TRIO Pharmaceuticals, a biotechnology company pioneering bispecific antibodies for the treatment of cancer with unprecedented potency and selectivity, announced the successful completion of a $3.1 million financing round. TRIO's pre-Series A financing was led by San Diego based Friedman Bioventure Fund (FBVF).

Additional significant support came from the Multiple Myeloma Research Foundation (MMRF), through its venture philanthropy arm, the Myeloma Investment Fund (MIF), underscoring the potential of TRIO's work to impact cancers with high unmet needs. Further investors included NuFund Venture Group, Life Science Angels and others.

TRIO Pharmaceuticals is a cancer immunotherapeutics company pioneering bispecific antibodies for the treatment of cancer with unprecedented potency and selectivity. TRIO's innovative antibody drugs directly stop tumor growth without affecting normal cells and selectively stop immunosuppression in the tumor without targeting the current immune checkpoint pathways. TRIO is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers of high unmet medical needs by targeting specific antigens on the cancer cells and immunosuppressor cells. TRIO has an experienced team that has developed first-in-class FDA-approved drugs.